| Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor S Gupta, S Tyagi, DV Almeida, MC Maiga, NC Ammerman, WR Bishai American journal of respiratory and critical care medicine 188 (5), 600-607, 2013 | 188 | 2013 |
| Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis S Chopra, K Matsuyama, T Tran, JP Malerich, B Wan, SG Franzblau, ... Journal of antimicrobial chemotherapy 67 (2), 415-421, 2012 | 111 | 2012 |
| Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model M Maiga, N Agarwal, NC Ammerman, R Gupta, H Guo, MC Maiga, S Lun, ... PLoS One 7 (2), e30749, 2012 | 83 | 2012 |
| Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment M Maiga, NC Ammerman, MC Maiga, A Tounkara, S Siddiqui, M Polis, ... The Journal of infectious diseases 208 (3), 512-519, 2013 | 52 | 2013 |
| Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis D Bhattacharya, VP Dwivedi, M Maiga, MC Maiga, L Van Kaer, WR Bishai, ... Journal of Biological Chemistry 289 (23), 16508-16515, 2014 | 47 | 2014 |
| Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis MC Maiga, BA Ahidjo, M Maiga, WR Bishai Antimicrobial agents and chemotherapy 59 (12), 7888-7890, 2015 | 34 | 2015 |
| Efficacy of adjunctive tofacitinib therapy in mouse models of tuberculosis M Maiga, BA Ahidjo, MC Maiga, L Cheung, S Pelly, S Lun, F Bougoudogo, ... EBioMedicine 2 (8), 868-873, 2015 | 29 | 2015 |
| Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams S Lun, D Miranda, A Kubler, H Guo, MC Maiga, K Winglee, S Pelly, ... MBio 5 (5), 2014 | 27 | 2014 |
| Rapid in vivo detection of isoniazid-sensitive Mycobacterium tuberculosis by breath test SW Choi, M Maiga, MC Maiga, V Atudorei, ZD Sharp, WR Bishai, ... Nature communications 5 (1), 1-6, 2014 | 20 | 2014 |
| The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis BA Ahidjo, MC Maiga, EA Ihms, M Maiga, AA Ordonez, LS Cheung, ... JCI insight 1 (14), 2016 | 16 | 2016 |
| In vitro and in vivo studies of a rapid and selective breath test for tuberculosis based upon mycobacterial CO dehydrogenase M Maiga, SW Choi, V Atudorei, MC Maiga, ZD Sharp, WR Bishai, ... MBio 5 (2), 2014 | 9 | 2014 |
| Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to ß-lactams. mBio 5: e01767-14 S Lun, D Miranda, A Kubler, H Guo, MC Maiga, K Winglee, S Pelly, ... | 6 | 2014 |
| Séroprévalence de la brucellose humaine à Mopti, Mali M MOPTI Revue Tunisienne d’Infectiologie-Oct 2, 24-26, 2009 | 4 | 2009 |
| Pirfenidone Exacerbates Granulomatous Inflammation And Disease Progression In Tuberculosis W Bishai, BA Ahidjo, MC Maiga, M Maiga, AA Ordonez, LS Cheung, ... A101. HOST DEFENSE, LUNG INJURY, AND FIBROSIS: INNATE MECHANISMS, A2640-A2640, 2016 | | 2016 |
| A101 HOST DEFENSE, LUNG INJURY, AND FIBROSIS: INNATE MECHANISMS: Pirfenidone Exacerbates Granulomatous Inflammation And Disease Progression In Tuberculosis W Bishai, BA Ahidjo, M Maiga, AA Ordonez, LS Cheung, S Beck, ... American Journal of Respiratory and Critical Care Medicine 193, 1, 2016 | | 2016 |
| Erratum to “Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis”[EBioMedicine 2 (8), August 2015, 868–873] M Maiga, BA Ahidjo, MC Maiga, L Cheung, S Pelly, S Lun, F Bougoudogo, ... EBioMedicine 2 (11), 1834, 2015 | | 2015 |
| Gene Expression of Mycobacterium tuberculosis Putative Transcription Factors C Larsson, B Luna, NC Ammerman, M Maiga, N Agarwal | | 2012 |
Mamoudou Maiga, MD, PhDNorthwestern UniversityAdresse e-mail validée de northwestern.edu
